TargetMol

Bavdegalutamide

Product Code:
 
TAR-T22263
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T22263-2mg2mg£139.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T22263-5mg5mg£182.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T22263-10mg10mg£244.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T22263-25mg25mg£411.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T22263-50mg50mg£508.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T22263-100mg100mg£701.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T22263-200mg200mg£946.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
ARV-110 is an oral degrader of androgen receptor PROTAC for prostate cancer treatment.
CAS:
2222112-77-6
Formula:
C41H43ClFN9O6
Molecular Weight:
812.3
Pathway:
Endocrinology/Hormones
Purity:
0.9904
SMILES:
Fc1cc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c2cc1N1CCN(CC2CCN(CC2)c2ccc(nn2)C(=O)N[C@H]2CC[C@@H](CC2)Oc2ccc(C#N)c(Cl)c2)CC1
Target:
Androgen Receptor

References

1. Taavi K Neklesa,et al. ARV-110: an oral androgen receptor PROTAC degrader for prostate cancer. GU ASCO 2019 2. Taavi Neklesa, et al. ARV-110: An androgen receptor PROTAC degrader for prostate cancer. American Association for Cancer Research. 2018. 78 (13): pp. 5236.